13F 19+/4-×0.0 · short↓0.24
Current snapshotPublic companyResearch currentFresh
BAXTER INTERNATIONAL INC
Package & Deliver · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Package & Deliver exposure in Healthspan Infrastructure.
- **BAX — Baxter International Inc.** — Historically operated BioPharma Solutions fill-finish CDMO; the business was divested to form Simtra BioPharma Solutions
Catalysts
Q3 2026 results before market open Thu Oct 29, 2026, call 7:30am CT (company release Oct 7, 2026). Q2 2026 (Jul 30): revenue $2.96B, +5.3% YoY, adj EPS $0.56 vs $0.37 consensus. Aug 18, 2026: early results and upsizing of cash tender offers for its notes (debt reduction path post-BioPharma Solutions separation to Simtra). [SEC 8-K 7/30/26 & 8/18/26]
Invalidation
needs primary source validation — pending deep-dive research. Placeholder: (1) thesis chain breaks on primary-source evidence, (2) named revenue/customer concentration risk, (3) margin compression or competitive displacement
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
| Fund / investor | As of | Fund portfolio weight | Evidence |
|---|---|---|---|
| iShares U.S. Medical Devices ETF IHI | 1.71% | Source |
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
needs primary source validation — no X/Reddit signal yet
Lower-confidence snapshotTarget price: $23.93
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Toll Road Tier
- Weak proxy
Timestamped research update
Deep research update
1,293 words · Updated 19 Oct 2026 · 7 sources
BAXTER INTERNATIONAL INC is a US-listed company materially exposed to Sterile Fill-Finish Capacity Economics.
Baxter International Inc. is a global medical products and therapies company. Its SEC disclosure framework historically segments the business into several operating areas. The company’s core economic model is hospital-critical consumables + installed equipment + recurring clinical use. The company is not primarily a software or services company; it is a regulated medical device and pharmaceutical/solution manufacturer with recurring disposable revenues attached to installed machines and clinical protocols.
The company’s 10-K business description should be pulled from:
- Baxter International Inc. Form 10-K, FY2024, Item 1 — SEC EDGAR filing index [2]
- Exact accession number: needs primary source validation
- Filing date: needs primary source validation
- Access date: 2026-04-27
Baxter’s historical segment presentation, before the separation of its kidney-care business, generally included:
| Segment | Business | Revenue mix status |
|---|---|---|
| Medical Products and Therapies | IV fluids, infusion pumps, administration sets, parenteral nutrition, surgical/hemostatic products | needs primary source validation |
| Healthcare Systems and Technologies | Hillrom hospital hardware: beds, nurse call, vital signs, care communications | needs primary source validation |
| Pharmaceuticals | Injectables, premixed drugs, inhalation anesthetics, compounding | needs primary source validation |
| Kidney Care / Vantive | Hemodialysis, peritoneal dialysis, CRRT products and solutions | needs primary source validation |
| BioPharma Solutions | Contract manufacturing for pharma customers | Divested/sold; continuing-ops status needs primary source validation |
Baxter’s buyers are generally:
- Acute care hospitals and health systems — purchasing through integrated delivery networks and group purchasing organizations.
- Dialysis clinics — both hospital-based and freestanding dialysis providers.
- Home dialysis programs — providers that ship PD supplies to patients’ homes.
- Pharmacy and compounding operations — hospital pharmacies and alternate-site pharmacies.
- Government and disaster preparedness stockpiles — sterile IV solutions can be strategic supply-chain products.
- Hospital supply-chain executives — focused on price, fill rates, safety stock, and supplier redundancy.
- Chief nursing officers / nurse managers — focused on infusion pump usability, training burden, and patient-safety features.
- Biomedical engineers — focused on device reliability, cybersecurity, integration, and service response.
- Dialysis medical directors/administrators — focused on per-treatment supply cost, reimbursement, patient outcomes, and home therapy logistics.
I will not invent customer names. The correct approach is to review:
- Baxter FY2024 10-K customer concentration and risk-factor disclosures.
- Competitor filings such as DaVita’s 10-K, which may name dialysis providers but does not necessarily prove Baxter’s customer relationships.
Any named customer in Baxter’s filing is:
needs primary source validation
- BAX — Baxter International Inc. — Historically operated BioPharma Solutions fill-finish CDMO; the business was divested to form Simtra BioPharma Solutions
- - BAX — Baxter International Inc. — Historically operated BioPharma Solutions fill-finish CDMO; the business was divested to form Simtra BioPharma Solutions source
\[
6{,}533 = 5{,}333
\]
\[
\text{Annual net profit} = (4 \times 156 \times 10) - 2{,}000 - \frac{20{,}000}{6}
\]
\[
= 6{,}240 - 2{,}000 - 3{,}333 = 907
\]
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| Baxter CIK | 0000010456 | SEC EDGAR [1] | Tier 1 | Measured | Yes — [1] and [2] |
| DaVita CIK | 0000927066 | SEC EDGAR [5] | Tier 1 | Measured | No |
| BAX FY2024 10-K exact accession | needs primary source validation | Pull from [1]/[2] | Tier 1 | Measured when pulled | No |
| BAX FY2024 revenue | needs primary source validation | BAX 10-K [2] | Tier 1 | Measured | No |
| BAX segment revenue mix | needs primary source validation | BAX 10-K segment note [2] | Tier 1 | Measured | No |
| BAX gross margin | needs primary source validation | BAX 10-K [2] | Tier 1 | Measured | No |
| BAX operating margin | needs primary source validation | BAX 10-K [2] | Tier 1 | Measured | No |
| BAX top customer names | needs primary source validation | BAX 10-K [2] | Tier 1 | Measured | No |
| DaVita supplier-dependence language | needs primary source validation | DaVita 10-K [4]/[5] | Tier 1 | Measured when pulled | No |
| CMS ESRD PPS payment rate | needs primary source validation | CMS [6] | Tier 1 | Measured | No |
| Patients per machine | 4 | Assumed | Tier 1 concept | Assumed | No |
| Treatments per patient-year | 156 | Derived formula | CMS ESRD PPS [6] | Derived | No |
| Consumable GP per treatment | $10.00 | Assumed | BAX segment margin, needs primary source validation | Assumed | No |
| Service cost per machine | $2,000 | Assumed | needs primary source validation | Assumed | No |
| Machine cost | $20,000 | Assumed | needs primary source validation | Assumed | No |
| Machine life | 6 years | Assumed | needs primary source validation | Assumed | No |
_Pending primary-source company deep-dive._
Baxter’s products are regulated medical devices, sterile pharmaceutical solutions, and hospital infrastructure. The technical functions are clinically critical and often embedded in provider protocols.
Products include:
- IV sodium chloride, dextrose, lactated Ringer’s, and sterile water solutions.
- Infusion pumps such as large-volume pumps, syringe pumps, and ambulatory pumps.
- Administration sets and access devices.
- Parenteral nutrition compounds.
- Premixed drug containers and drug-reconstitution systems.
Baxter has some pricing power in shortage periods or sole-source contracts, but large hospital group purchasing organizations often force competitive bidding. Long-term pricing trends in IV fluids are generally not strong; specific price/mix data is needs primary source validation.
In the U.S., ESRD reimbursement is set under the Medicare ESRD Prospective Payment System. A provider’s supply cost is heavily influenced by CMS rates. Baxter’s pricing power is therefore partially limited by external reimbursement. The exact CMS base rate and product-level economics must be sourced from:
- CMS ESRD PPS page [6]
- Baxter 10-K segment and pricing disclosures [2]
Any asserted CMS payment rate or Baxter renal margin is needs primary source validation.
Premixed and ready-to-use products can command premium pricing because they reduce hospital labor and compounding errors, but generic therapies face continued price erosion. Exact pricing and portfolio contribution are needs primary source validation.
This is the Hillrom-derived business, including:
- Hospital beds and surfaces.
- Nurse call systems.
- Vital signs monitors and physical assessment devices.
- Care communication and digital health infrastructure.
Capital budgeting for this segment is more cyclical than consumables. Hospitals can defer capital purchases in tight financial periods. Therefore pricing power is weaker than in sterile consumables, especially outside a hospital-wide integration contract.
_Pending primary-source company deep-dive._
The investment thesis on BAX would be wrong or materially weakened if any of the following appears in primary filings:
- DaVita or Fresenius discloses successful dual-sourcing or in-house supply of dialysis products. This would contradict the razor/razor-blade pricing-power assumption. Any such competitor-filing language must be verified directly against the competitor 10-K/20-F.
- Baxter’s renal segment revenue is more concentrated and contract-dependent than the segment narrative suggests. If a large customer is >10% of revenue or if major contracts have near-term expirations, the customer-switching risk is higher than assumed.
- Baxter’s gross margin in Medical Products and Therapies is declining due to IV fluid price erosion. This would show that hospital GPO buyer power exceeds any scale/manufacturing barrier.
- The Vantive separation leaves remaining Baxter with lower recurring revenue intensity. If the post-separation continuing operations have materially lower consumable mix and higher capital-equipment cyclicality, the residual business is structurally lower quality.
- CMS materially cuts ESRD PPS reimbursement or shifts reimbursement toward oral/kidney-care alternatives. This would reduce provider willingness to buy Baxter dialysis products.
- The unit-economics model breaks even only above $8.55 consumable gross profit per treatment under the illustrative assumptions. If primary-segment data show actual consumable gross profit is near or below that threshold, the capital-placement model is not economically attractive.
- The 10-K reveals that a significant share of Baxter’s manufacturing capacity is exposed to a single facility or geographic concentration. This would create supply-shock risk not captured by the normal pricing-power narrative.
All disconfirming items must be tested against the FY2024 10-K, Baxter 8-Ks, and competitor filings before final conviction is assigned.
INTACT (exposure surfaced from technology map; no capital allocation)
Primary and supporting material
Sources
7 sources preserved from the latest qualified research update.